CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF621 (ImmuneEditome ID:285268)

1. Gene summary of enriched editing regions for ZNF621

check button Gene summary
Gene informationGene symbol

ZNF621

Gene ID

285268

GeneSynonyms-
GeneCytomap

3p22.1

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 621
GeneModificationdate20230329
UniprotIDQ6ZSS3;C9JZC2;C9JM43
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:40536071-40538990:+ENST00000310898.4ENSG00000172888.10ZNF621exonicAluJr,AluSz,Tigger1chr3:40536071-40538990:+.alignment
chr3:40553446-40553663:+ENST00000490457.4ENSG00000172888.10ZNF621ncRNA_intronicL1MC4a,AluYchr3:40553446-40553663:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF621


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr3:40536071-40538990:+KIRPEER3.1782e-02image
ENSG00000172888.10,ZNF621KIRPEAG3.5300e-02image
chr3:40536071-40538990:+LUSCEER4.3488e-02image
ENSG00000172888.10,ZNF621LUSCEAG4.5891e-02image
chr3:40536071-40538990:+THCAEER4.2389e-02image
ENSG00000172888.10,ZNF621THCAEAG3.3713e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr3:40536071-40538990:+LUADPathEER3.7822e-024.7829e-030.1292image
ENSG00000172888.10,ZNF621LUADPathEAG3.7636e-024.7114e-030.1295image
chr3:40536071-40538990:+TGCTPathEER3.8837e-022.4151e-020.3038image
ENSG00000172888.10,ZNF621TGCTPathEAG3.8837e-022.4151e-020.3038image
ENSG00000172888.10,ZNF621UVMCliEAG4.5893e-021.3271e-020.3480image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr3:40536071-40538990:+COADEER1.3004e-021.3954e-029.5245e-03image
ENSG00000172888.10,ZNF621COADEAG1.3004e-021.3954e-029.5245e-03image
chr3:40536071-40538990:+KIRPEER3.5230e-021.3447e-049.7834e+03image
ENSG00000172888.10,ZNF621KIRPEAG3.5230e-021.1443e-041.1232e+04image

Top

3. Enriched editing regions and immune related genes for ZNF621


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:40536071-40538990:+COADEERENSG00000242407,CTD-2377D24.40.17752.0205e-026.1107e-120.4082imageNNNADendritic_cells_activatedGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr3:40536071-40538990:+GBMEERENSG00000234498,RPL13AP200.37662.4691e-049.4796e-170.5899imageNNNAT_cells_gamma_deltaGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr3:40536071-40538990:+GBMEERENSG00000250956,CTB-88F18.30.37243.3032e-047.4817e-160.5756imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr3:40536071-40538990:+GBMEERENSG00000232888,RPS11P50.36025.6093e-043.2430e-120.5095imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_APICAL_JUNCTION
chr3:40536071-40538990:+GBMEERENSG00000223668,EEF1A1P240.36065.7289e-042.9573e-140.5483imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:40536071-40538990:+GBMEERENSG00000236735,RPL31P630.36086.3827e-047.7530e-260.7038imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_APICAL_JUNCTION
chr3:40536071-40538990:+GBMEERENSG00000242858,CTC-484M2.10.35716.4450e-042.3509e-140.5501imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr3:40536071-40538990:+GBMEERENSG00000213235,EEF1A1P160.35506.8817e-041.0939e-140.5560imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr3:40536071-40538990:+GBMEERENSG00000243746,EEF1A1P100.35527.0829e-045.3145e-140.5437imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MYC_TARGETS_V1
chr3:40536071-40538990:+GBMEERENSG00000267119,RPL10P150.35787.6803e-045.6438e-110.4832imageNNNANK_cells_restingGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

More results



Top

4. Enriched editing regions and immune related splicing for ZNF621


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000172888.10,ZNF621
CESCEAGIRENSG00000226742.3chr1879966611:79966678:79968094:79968183-0.24329.7994e-033.9053e-10-0.4001imageNADAR;AUH;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP3;KHDRBS2;LIN28;LIN28B;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184HSBP1L1B_cells_naiveGSVA_HALLMARK_HYPOXIA
chr3:40536071-40538990:+
COADEERESENSG00000104228.8chr827294079:27294310:27298463:27298559:27310800:27310856-0.17022.6495e-021.4292e-10-0.4406imageNNTRIM35Mast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
ENSG00000172888.10,ZNF621
COADEAGESENSG00000104228.8chr827294079:27294310:27298463:27298559:27310800:27310856-0.17023.0156e-021.4292e-10-0.4406imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184TRIM35Mast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr3:40536071-40538990:+
TGCTEERIRENSG00000115289.8chr274506731:74507147:74507357:74507417-0.35722.9663e-033.8026e-05-0.4015imageNNNANK_cells_restingGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000172888.10,ZNF621
TGCTEAGIRENSG00000123737.8chr4121813754:121814047:121816389:121816447-0.19264.0586e-025.1669e-05-0.4049imageNADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184NAGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr3:40536071-40538990:+
TGCTEERMEXENSG00000129657.10chr1777215922:77215935:77216023:77216062:77216062:77216140:77216348:77216387-0.16931.8620e-021.0630e-05-0.4208imageNNNAGSVA_HALLMARK_TGF_BETA_SIGNALING
ENSG00000172888.10,ZNF621
TGCTEAGMEXENSG00000129657.10chr1777215922:77215935:77216023:77216036:77216062:77216244:77216348:77216802-0.15774.6641e-025.3011e-07-0.4664imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
chr3:40536071-40538990:+
TGCTEERESENSG00000141068.9chr1727601359:27601401:27601892:27601958:27603833:276038880.35157.7891e-043.7686e-060.4458imageNNNAB_cells_naiveGSVA_HALLMARK_HYPOXIA
ENSG00000172888.10,ZNF621
TGCTEAGESENSG00000141068.9chr1727601359:27601401:27601892:27601958:27603833:276038880.35265.5887e-043.5579e-060.4468imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAB_cells_naiveGSVA_HALLMARK_HYPOXIA
chr3:40536071-40538990:+
TGCTEERIRENSG00000123737.8chr4121813754:121814047:121816389:121816447-0.19184.4436e-025.2805e-05-0.4044imageNNNAGSVA_HALLMARK_ALLOGRAFT_REJECTION

More results



Top

5. Enriched editing regions and immune infiltration for ZNF621


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr3:40536071-40538990:+BLCAEERT_cells_CD4_memory_activated1.6413e-020.1273image
ENSG00000172888.10,ZNF621BLCAEAGT_cells_CD4_memory_activated1.4549e-020.1294image
chr3:40536071-40538990:+BRCAEERNK_cells_activated7.6749e-030.0827image
ENSG00000172888.10,ZNF621BRCAEAGNK_cells_activated4.7192e-030.0874image
chr3:40536071-40538990:+CESCEERMacrophages_M22.0597e-02-0.1455image
ENSG00000172888.10,ZNF621CESCEAGMacrophages_M21.9139e-02-0.1469image
chr3:40536071-40538990:+CHOLEERMast_cells_resting4.6128e-020.3496image
chr3:40536071-40538990:+COADEERMast_cells_activated1.5076e-020.1500image
ENSG00000172888.10,ZNF621COADEAGMast_cells_activated1.5076e-020.1500image
chr3:40536071-40538990:+ESCAEERT_cells_gamma_delta6.5624e-040.2707image
ENSG00000172888.10,ZNF621ESCAEAGT_cells_gamma_delta6.0454e-040.2725image
chr3:40536071-40538990:+GBMEERT_cells_follicular_helper2.6367e-030.2334image
ENSG00000172888.10,ZNF621GBMEAGT_cells_follicular_helper2.6004e-030.2337image
chr3:40536071-40538990:+HNSCEERMast_cells_resting3.7263e-020.1073image
ENSG00000172888.10,ZNF621HNSCEAGMast_cells_resting3.6293e-020.1079image
chr3:40536071-40538990:+KIRCEERNK_cells_resting3.7543e-02-0.1089image
ENSG00000172888.10,ZNF621KIRCEAGNK_cells_resting3.6070e-02-0.1098image
chr3:40536071-40538990:+KIRPEERNK_cells_resting4.7181e-030.1754image
ENSG00000172888.10,ZNF621KIRPEAGNK_cells_resting4.7711e-030.1748image
ENSG00000172888.10,ZNF621LAMLEAGEosinophils1.8039e-020.1968image
ENSG00000172888.10,ZNF621LGGEAGB_cells_memory1.0954e-020.1110image
chr3:40536071-40538990:+LIHCEERDendritic_cells_resting7.1584e-03-0.1781image
ENSG00000172888.10,ZNF621LIHCEAGDendritic_cells_resting7.4783e-03-0.1767image
chr3:40536071-40538990:+LUADEERT_cells_CD4_memory_resting4.5785e-03-0.1300image
ENSG00000172888.10,ZNF621LUADEAGT_cells_CD4_memory_resting3.6072e-03-0.1334image
chr3:40536071-40538990:+LUSCEERB_cells_naive2.3320e-02-0.1055image
ENSG00000172888.10,ZNF621LUSCEAGB_cells_naive2.3000e-02-0.1058image
chr3:40536071-40538990:+MESOEERDendritic_cells_activated2.1199e-030.3450image
ENSG00000172888.10,ZNF621MESOEAGDendritic_cells_activated2.0934e-030.3454image
chr3:40536071-40538990:+OVEERB_cells_memory2.7861e-020.1429image
ENSG00000172888.10,ZNF621OVEAGMacrophages_M21.3123e-020.1602image
chr3:40536071-40538990:+PAADEERMast_cells_activated3.9609e-020.1604image
ENSG00000172888.10,ZNF621PAADEAGMast_cells_activated3.6188e-020.1632image
chr3:40536071-40538990:+PCPGEERMacrophages_M23.1299e-020.1693image
ENSG00000172888.10,ZNF621PCPGEAGMacrophages_M23.1891e-020.1676image
chr3:40536071-40538990:+PRADEERNK_cells_activated3.6351e-020.0980image
ENSG00000172888.10,ZNF621PRADEAGT_cells_regulatory_(Tregs)3.3390e-020.0988image
ENSG00000172888.10,ZNF621READEAGDendritic_cells_resting1.2768e-020.2601image
chr3:40536071-40538990:+SARCEEREosinophils9.7237e-030.1713image
ENSG00000172888.10,ZNF621SARCEAGEosinophils9.1882e-030.1722image
chr3:40536071-40538990:+SKCMEERT_cells_follicular_helper5.2288e-030.1338image
ENSG00000172888.10,ZNF621SKCMEAGT_cells_follicular_helper5.6952e-030.1325image
chr3:40536071-40538990:+STADEERT_cells_CD4_memory_resting9.5585e-03-0.1414image
ENSG00000172888.10,ZNF621STADEAGT_cells_CD4_memory_resting7.3633e-03-0.1462image
chr3:40536071-40538990:+TGCTEERNK_cells_resting5.1908e-03-0.2568image
ENSG00000172888.10,ZNF621TGCTEAGNK_cells_resting5.2033e-03-0.2567image
chr3:40536071-40538990:+THCAEERMast_cells_resting1.8851e-02-0.1080image
ENSG00000172888.10,ZNF621THCAEAGMast_cells_resting1.6878e-02-0.1094image
chr3:40536071-40538990:+THYMEERT_cells_CD4_memory_activated1.2178e-030.3532image
ENSG00000172888.10,ZNF621THYMEAGT_cells_CD4_memory_activated1.1142e-030.3496image
chr3:40536071-40538990:+UCECEEREosinophils1.9112e-02-0.1986image
ENSG00000172888.10,ZNF621UCECEAGEosinophils4.8077e-02-0.1650image
ENSG00000172888.10,ZNF621UCSEAGMacrophages_M22.3619e-02-0.3369image
ENSG00000172888.10,ZNF621UVMEAGT_cells_CD4_naive1.2243e-020.3518image


Top

6. Enriched editing regions and immune gene sets for ZNF621


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr3:40536071-40538990:+BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.5624e-030.1673image
ENSG00000172888.10,ZNF621BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.2996e-030.1611image
ENSG00000172888.10,ZNF621BRCAGSVA_HALLMARK_HYPOXIAEAG8.0132e-070.1520image
chr3:40536071-40538990:+BRCAGSVA_HALLMARK_HYPOXIAEER5.4102e-060.1406image
ENSG00000172888.10,ZNF621CESCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.0931e-030.2037image
chr3:40536071-40538990:+CESCGSVA_HALLMARK_KRAS_SIGNALING_DNEER7.9626e-030.1665image
ENSG00000172888.10,ZNF621CHOLGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.0307e-02-0.3719image
ENSG00000172888.10,ZNF621DLBCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.5238e-020.4557image
chr3:40536071-40538990:+DLBCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.5238e-020.4557image
ENSG00000172888.10,ZNF621ESCAGSVA_HALLMARK_P53_PATHWAYEAG2.2856e-020.1827image
chr3:40536071-40538990:+ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.0471e-02-0.1860image
chr3:40536071-40538990:+GBMGSVA_HALLMARK_HEME_METABOLISMEER2.8469e-04-0.2798image
ENSG00000172888.10,ZNF621GBMGSVA_HALLMARK_HEME_METABOLISMEAG2.5832e-04-0.2817image
chr3:40536071-40538990:+KICHGSVA_HALLMARK_APICAL_SURFACEEER2.2969e-02-0.2862image
ENSG00000172888.10,ZNF621KICHGSVA_HALLMARK_APICAL_SURFACEEAG2.3124e-02-0.2859image
chr3:40536071-40538990:+KIRCGSVA_HALLMARK_GLYCOLYSISEER1.7980e-030.1629image
ENSG00000172888.10,ZNF621KIRCGSVA_HALLMARK_GLYCOLYSISEAG3.8095e-030.1511image
ENSG00000172888.10,ZNF621KIRPGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.8319e-020.1465image
chr3:40536071-40538990:+KIRPGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.6655e-020.1490image
ENSG00000172888.10,ZNF621LAMLGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.0795e-03-0.2697image
chr3:40536071-40538990:+LGGGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.2421e-03-0.1332image
ENSG00000172888.10,ZNF621LGGGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.5486e-03-0.1378image
chr3:40536071-40538990:+LIHCGSVA_HALLMARK_FATTY_ACID_METABOLISMEER6.2901e-030.1808image
ENSG00000172888.10,ZNF621LIHCGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG5.0242e-030.1852image
chr3:40536071-40538990:+LUADGSVA_HALLMARK_UV_RESPONSE_UPEER5.0895e-040.1591image
ENSG00000172888.10,ZNF621LUADGSVA_HALLMARK_UV_RESPONSE_UPEAG4.7170e-040.1600image
ENSG00000172888.10,ZNF621MESOGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.1028e-020.2882image
chr3:40536071-40538990:+MESOGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.0872e-020.2887image
chr3:40536071-40538990:+OVGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.3010e-030.1971image
ENSG00000172888.10,ZNF621OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG5.4036e-030.1794image
ENSG00000172888.10,ZNF621PAADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.5406e-02-0.1740image
chr3:40536071-40538990:+PAADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.7390e-02-0.1850image
chr3:40536071-40538990:+PCPGGSVA_HALLMARK_SPERMATOGENESISEER2.7168e-02-0.1736image
ENSG00000172888.10,ZNF621PCPGGSVA_HALLMARK_SPERMATOGENESISEAG2.0689e-02-0.1806image
chr3:40536071-40538990:+PRADGSVA_HALLMARK_P53_PATHWAYEER8.8883e-040.1551image
ENSG00000172888.10,ZNF621PRADGSVA_HALLMARK_P53_PATHWAYEAG1.0310e-030.1519image
ENSG00000172888.10,ZNF621READGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.0547e-04-0.3527image
chr3:40536071-40538990:+SARCGSVA_HALLMARK_MYC_TARGETS_V2EER1.2179e-020.1662image
ENSG00000172888.10,ZNF621SARCGSVA_HALLMARK_MYC_TARGETS_V2EAG1.6089e-020.1593image
ENSG00000172888.10,ZNF621SKCMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.8426e-040.1786image
chr3:40536071-40538990:+SKCMGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.9137e-040.1781image
chr3:40536071-40538990:+STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.7113e-030.1707image
ENSG00000172888.10,ZNF621STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.3287e-030.1747image
ENSG00000172888.10,ZNF621TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG2.1875e-02-0.2118image
chr3:40536071-40538990:+TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.2947e-02-0.2102image
ENSG00000172888.10,ZNF621THCAGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG2.5275e-040.1668image
chr3:40536071-40538990:+THCAGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER3.4533e-040.1639image
ENSG00000172888.10,ZNF621THYMGSVA_HALLMARK_MYC_TARGETS_V2EAG1.1512e-020.2745image
chr3:40536071-40538990:+THYMGSVA_HALLMARK_HEME_METABOLISMEER7.4462e-03-0.2953image
ENSG00000172888.10,ZNF621UCECGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.7198e-02-0.1983image
chr3:40536071-40538990:+UCECGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.8537e-020.1676image
ENSG00000172888.10,ZNF621UCSGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.4967e-02-0.3152image
ENSG00000172888.10,ZNF621UVMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG7.4786e-040.4613image


Top

7. Enriched editing regions and drugs for ZNF621


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000172888.10,ZNF621ACCLFM.A13EAG2.3676e-02-0.2848image
chr3:40536071-40538990:+BLCACyclopamineEER5.1686e-03-0.1481image
ENSG00000172888.10,ZNF621BLCACyclopamineEAG5.6539e-03-0.1464image
ENSG00000172888.10,ZNF621BRCAA.770041EAG3.8918e-07-0.1564image
chr3:40536071-40538990:+BRCADasatinibEER7.3243e-06-0.1388image
ENSG00000172888.10,ZNF621CESCErlotinibEAG2.9734e-06-0.2884image
chr3:40536071-40538990:+CESCErlotinibEER2.6871e-03-0.1879image
chr3:40536071-40538990:+COADLFM.A13EER1.1960e-02-0.1551image
ENSG00000172888.10,ZNF621COADLFM.A13EAG1.1960e-02-0.1551image
ENSG00000172888.10,ZNF621DLBCGW.441756EAG2.8890e-03-0.5813image
chr3:40536071-40538990:+DLBCGW.441756EER2.8890e-03-0.5813image
ENSG00000172888.10,ZNF621ESCAKU.55933EAG2.2566e-05-0.3343image
chr3:40536071-40538990:+ESCAKU.55933EER1.5612e-05-0.3404image
ENSG00000172888.10,ZNF621GBMElesclomolEAG6.9545e-08-0.4059image
chr3:40536071-40538990:+GBMElesclomolEER7.5235e-08-0.4049image
chr3:40536071-40538990:+HNSCElesclomolEER8.4339e-030.1355image
ENSG00000172888.10,ZNF621HNSCElesclomolEAG8.9862e-030.1344image
ENSG00000172888.10,ZNF621KICHBexaroteneEAG3.9958e-030.3577image
chr3:40536071-40538990:+KICHBexaroteneEER3.3417e-030.3642image
ENSG00000172888.10,ZNF621KIRCJNK.Inhibitor.VIIIEAG2.3934e-040.1911image
chr3:40536071-40538990:+KIRCAZD6482EER2.4404e-040.1914image
ENSG00000172888.10,ZNF621KIRPAZD.2281EAG4.1721e-04-0.2177image
chr3:40536071-40538990:+KIRPAZD.2281EER5.3604e-04-0.2141image
ENSG00000172888.10,ZNF621LAMLAMG.706EAG2.9289e-020.1817image
chr3:40536071-40538990:+LGGAMG.706EER2.7026e-07-0.2226image
ENSG00000172888.10,ZNF621LGGAMG.706EAG8.7507e-07-0.2129image
chr3:40536071-40538990:+LIHCCHIR.99021EER1.7494e-020.1713image
ENSG00000172888.10,ZNF621LIHCCHIR.99021EAG1.3088e-020.1783image
ENSG00000172888.10,ZNF621LUADA.770041EAG1.5693e-04-0.1728image
chr3:40536071-40538990:+LUADA.770041EER1.6892e-04-0.1719image
chr3:40536071-40538990:+LUSCA.770041EER1.3781e-02-0.1145image
ENSG00000172888.10,ZNF621LUSCA.770041EAG1.3333e-02-0.1151image
chr3:40536071-40538990:+MESOBMS.536924EER7.5597e-04-0.3758image
ENSG00000172888.10,ZNF621MESOBMS.536924EAG7.4326e-04-0.3763image
ENSG00000172888.10,ZNF621OVBMS.536924EAG1.6680e-04-0.2412image
chr3:40536071-40538990:+OVBMS.536924EER3.7153e-04-0.2293image
chr3:40536071-40538990:+PAADAxitinibEER1.7837e-030.2436image
ENSG00000172888.10,ZNF621PAADAxitinibEAG1.3255e-030.2502image
chr3:40536071-40538990:+PCPGAZD.2281EER2.8774e-03-0.2328image
ENSG00000172888.10,ZNF621PCPGGefitinibEAG2.5952e-03-0.2337image
ENSG00000172888.10,ZNF621PRADCI.1040EAG8.4268e-04-0.1545image
chr3:40536071-40538990:+PRADAZ628EER9.3150e-04-0.1549image
ENSG00000172888.10,ZNF621READJNK.Inhibitor.VIIIEAG5.4264e-030.2892image
ENSG00000172888.10,ZNF621SARCCCT007093EAG4.4362e-030.1878image
chr3:40536071-40538990:+SARCCCT007093EER2.0158e-030.2039image
ENSG00000172888.10,ZNF621SKCMBIBW2992EAG6.0744e-13-0.3364image
chr3:40536071-40538990:+SKCMBIBW2992EER9.8135e-13-0.3335image
ENSG00000172888.10,ZNF621STADBMS.536924EAG3.6720e-04-0.1935image
chr3:40536071-40538990:+STADBMS.536924EER2.9288e-04-0.1967image
ENSG00000172888.10,ZNF621TGCTGefitinibEAG1.0623e-02-0.2354image
chr3:40536071-40538990:+TGCTGefitinibEER1.0870e-02-0.2347image
chr3:40536071-40538990:+THCABMS.708163EER2.0696e-03-0.1413image
ENSG00000172888.10,ZNF621THCABMS.708163EAG2.4469e-03-0.1384image
chr3:40536071-40538990:+THYMAZD6244EER9.6243e-05-0.4197image
ENSG00000172888.10,ZNF621THYMAZD.2281EAG2.7802e-03-0.3224image
chr3:40536071-40538990:+UCECAKT.inhibitor.VIIIEER2.4778e-020.1904image
ENSG00000172888.10,ZNF621UCECAZD6244EAG5.4073e-05-0.3298image
ENSG00000172888.10,ZNF621UCSBortezomibEAG2.1446e-020.3421image
ENSG00000172888.10,ZNF621UVMJW.7.52.1EAG2.9636e-04-0.4908image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType